These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31423922)

  • 1. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial.
    King BT; Lawrence PD; Milling TJ; Warach SJ
    Int J Stroke; 2019 Dec; 14(9):977-982. PubMed ID: 31423922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.
    Best JG; Arram L; Ahmed N; Balogun M; Bennett K; Bordea E; Campos MG; Caverly E; Chau M; Cohen H; Dehbi HM; Doré CJ; Engelter ST; Fenner R; Freemantle N; Hunter R; James M; Lip GY; Murray ML; Norrving B; Sprigg N; Veltkamp R; Zaczyk I; Werring DJ;
    Int J Stroke; 2022 Jun; 17(5):583-589. PubMed ID: 35018878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial.
    Åsberg S; Hijazi Z; Norrving B; Terént A; Öhagen P; Oldgren J
    Trials; 2017 Dec; 18(1):581. PubMed ID: 29197413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
    van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
    Trials; 2015 Sep; 16():393. PubMed ID: 26340977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.
    Seiffge DJ; Werring DJ; Paciaroni M; Dawson J; Warach S; Milling TJ; Engelter ST; Fischer U; Norrving B
    Lancet Neurol; 2019 Jan; 18(1):117-126. PubMed ID: 30415934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.
    Hong KS; Choi YJ; Kwon SU;
    Int J Stroke; 2015 Jan; 10(1):128-33. PubMed ID: 25346499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
    Verma A; Ha ACT; Kirchhof P; Hindricks G; Healey JS; Hill MD; Sharma M; Wyse DG; Champagne J; Essebag V; Wells G; Gupta D; Heidbuchel H; Sanders P; Birnie DH
    Am Heart J; 2018 Mar; 197():124-132. PubMed ID: 29447772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.
    Fischer U; Koga M; Strbian D; Branca M; Abend S; Trelle S; Paciaroni M; Thomalla G; Michel P; Nedeltchev K; Bonati LH; Ntaios G; Gattringer T; Sandset EC; Kelly P; Lemmens R; Sylaja PN; Aguiar de Sousa D; Bornstein NM; Gdovinova Z; Yoshimoto T; Tiainen M; Thomas H; Krishnan M; Shim GC; Gumbinger C; Vehoff J; Zhang L; Matsuzono K; Kristoffersen E; Desfontaines P; Vanacker P; Alonso A; Yakushiji Y; Kulyk C; Hemelsoet D; Poli S; Paiva Nunes A; Caracciolo N; Slade P; Demeestere J; Salerno A; Kneihsl M; Kahles T; Giudici D; Tanaka K; Räty S; Hidalgo R; Werring DJ; Göldlin M; Arnold M; Ferrari C; Beyeler S; Fung C; Weder BJ; Tatlisumak T; Fenzl S; Rezny-Kasprzak B; Hakim A; Salanti G; Bassetti C; Gralla J; Seiffge DJ; Horvath T; Dawson J;
    N Engl J Med; 2023 Jun; 388(26):2411-2421. PubMed ID: 37222476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation-A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation.
    Rose DZ; Meriwether JN; Fradley MG; Renati S; Martin RC; Kasprowicz T; Patel A; Mokin M; Murtagh R; Kip K; Bozeman AC; McTigue T; Hilker N; Kirby B; Wick N; Tran N; Burgin WS; Labovitz AJ
    Front Neurol; 2019; 10():975. PubMed ID: 31620067
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial.
    Hong KS; Kwon SU; Lee SH; Lee JS; Kim YJ; Song TJ; Kim YD; Park MS; Kim EG; Cha JK; Sung SM; Yoon BW; Bang OY; Seo WK; Hwang YH; Ahn SH; Kang DW; Kang HG; Yu KH;
    JAMA Neurol; 2017 Oct; 74(10):1206-1215. PubMed ID: 28892526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study.
    Kimura S; Toyoda K; Yoshimura S; Minematsu K; Yasaka M; Paciaroni M; Werring DJ; Yamagami H; Nagao T; Yoshimura S; Polymeris A; Zietz A; Engelter ST; Kallmünzer B; Cappellari M; Chiba T; Yoshimoto T; Shiozawa M; Kitazono T; Koga M;
    Stroke; 2022 May; 53(5):1540-1549. PubMed ID: 35105180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation.
    Smythe MA; Parker D; Garwood CL; Cuker A; Messé SR
    Pharmacotherapy; 2020 Jan; 40(1):55-71. PubMed ID: 31698510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation.
    Audebert HJ; Schenk B; Schenkel J; Heuschmann PU
    Cerebrovasc Dis; 2010; 29(5):476-83. PubMed ID: 20299787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Apixaban Use Following Stroke in Patients With Atrial Fibrillation: Results of the AREST Trial.
    Labovitz AJ; Rose DZ; Fradley MG; Meriwether JN; Renati S; Martin R; Kasprowicz T; Murtagh R; Kip K; Beckie TM; Stoddard M; Bozeman AC; McTigue T; Kirby B; Tran N; Burgin WS;
    Stroke; 2021 Apr; 52(4):1164-1171. PubMed ID: 33626904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
    Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
    Masjuan J; DeFelipe A
    Int J Neurosci; 2017 Aug; 127(8):716-725. PubMed ID: 27586690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.